Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Shida-Kawazoe M"" wg kryterium: Wszystkie pola


Tytuł:
Novel myostatin-specific antibody enhances muscle strength in muscle disease models.
Autorzy:
Muramatsu H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Kuramochi T; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
Katada H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Ueyama A; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Ruike Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Ohmine K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Miyano-Nishizawa R; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Shimizu Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Okuda M; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
Hori Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Hayashi M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Haraya K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Ban N; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Nonaka T; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Honda M; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Kitamura H; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Hattori K; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Igawa T; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, Singapore, 138623, Singapore.
Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan.
Nezu J; Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, 103-8324, Japan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Jan 25; Vol. 11 (1), pp. 2160. Date of Electronic Publication: 2021 Jan 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal/*pharmacology
Muscle Strength/*drug effects
Muscular Diseases/*physiopathology
Myostatin/*immunology
Animals ; Bone Morphogenetic Proteins/metabolism ; Disease Models, Animal ; Female ; Growth Differentiation Factors/metabolism ; Macaca fascicularis ; Male ; Mice, Inbred C57BL ; Muscle, Skeletal/pathology ; Muscle, Skeletal/physiopathology ; Muscular Atrophy/pathology ; Muscular Atrophy/physiopathology ; Organ Size ; Signal Transduction ; Mice
Czasopismo naukowe
Tytuł:
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.
Autorzy:
Sampei Z; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Haraya K; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Tachibana T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Fukuzawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Gan SW; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Shimizu Y; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Ruike Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Feng S; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Kuramochi T; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Muraoka M; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
Igawa T; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.
Hattori K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Nezu J; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Dec 28; Vol. 13 (12), pp. e0209509. Date of Electronic Publication: 2018 Dec 28 (Print Publication: 2018).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal/*genetics
Complement Activation/*drug effects
Complement C5/*antagonists & inhibitors
Protein Engineering/*methods
Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antibody Affinity ; Complement Activation/immunology ; Complement C5/immunology ; Complement C5/isolation & purification ; Computer Simulation ; Drug Discovery/methods ; Endosomes/immunology ; Histocompatibility Antigens Class I/genetics ; Histocompatibility Antigens Class I/immunology ; Humans ; Hydrogen-Ion Concentration ; Immune System Diseases/drug therapy ; Immune System Diseases/immunology ; Macaca fascicularis ; Mice ; Mice, Transgenic ; Mutagenesis ; Receptors, Fc/genetics ; Receptors, Fc/immunology ; Recombinant Proteins/immunology ; Recombinant Proteins/isolation & purification ; Time Factors
Czasopismo naukowe
Tytuł:
The P2X7 Receptor in Oncogenesis and Metastatic Dissemination: New Insights on Vesicular Release and Adenosinergic Crosstalk.
Autorzy:
Adinolfi, Elena (AUTHOR)
De Marchi, Elena (AUTHOR)
Grignolo, Marianna (AUTHOR)
Szymczak, Bartosz (AUTHOR)
Pegoraro, Anna (AUTHOR)
Pokaż więcej
Źródło:
International Journal of Molecular Sciences. Sep2023, Vol. 24 Issue 18, p13906. 15p.
Czasopismo naukowe
Tytuł:
Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH.
Autorzy:
Liu, Xiaoyu (AUTHOR)
Tan, Qingqing (AUTHOR)
Wen, Jiaqi (AUTHOR)
Wang, Xufei (AUTHOR)
Yang, Gang (AUTHOR)
Li, Yuxiao (AUTHOR)
Lu, Ming (AUTHOR)
Ye, Wei (AUTHOR)
Si, Anfeng (AUTHOR)
Ma, Sujuan (AUTHOR)
Ding, Tong (AUTHOR)
Sun, Luan (AUTHOR)
Liu, Fang (AUTHOR)
Zhang, Mei (AUTHOR)
Jiang, Tao (AUTHOR)
Gao, Wei (AUTHOR)
Pokaż więcej
Źródło:
Journal of Translational Medicine. 8/25/2023, Vol. 21 Issue 1, p1-15. 15p.
Czasopismo naukowe
Tytuł:
Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement.
Autorzy:
Sampei, Zenjiro (AUTHOR)
Koo, Christine Xing'er (AUTHOR)
Teo, Frannie Jiuyi (AUTHOR)
Toh, Ying Xiu (AUTHOR)
Fukuzawa, Taku (AUTHOR)
Gan, Siok Wan (AUTHOR)
Nambu, Takeru (AUTHOR)
Ho, Adrian (AUTHOR)
Honda, Kiyofumi (AUTHOR)
Igawa, Tomoyuki (AUTHOR)
Ahmed, Fariyal (AUTHOR)
Wang, Cheng-I (AUTHOR)
Fink, Katja (AUTHOR)
Nezu, Junichi (AUTHOR)
Pokaż więcej
Źródło:
Antibodies (2073-4468). Jun2023, Vol. 12 Issue 2, p36. 13p.
Czasopismo naukowe
Tytuł:
A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
Autorzy:
Cheng, Lian-sheng (AUTHOR)
Cheng, Yong-feng (AUTHOR)
Liu, Wen-ting (AUTHOR)
Shen, Aolin (AUTHOR)
Zhang, Dayan (AUTHOR)
Xu, Tingjuan (AUTHOR)
Yin, Wu (AUTHOR)
Cheng, Min (AUTHOR)
Ma, Xiaopeng (AUTHOR)
Wang, Fengrong (AUTHOR)
Zhao, Qun (AUTHOR)
Zeng, Xiaoli (AUTHOR)
Zhang, Yan (AUTHOR)
Shen, Guodong (AUTHOR)
Pokaż więcej
Źródło:
Journal of Translational Medicine. 9/8/2022, Vol. 20 Issue 1, p1-18. 18p.
Czasopismo naukowe
Tytuł:
PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery.
Autorzy:
Ortona, Silvia (AUTHOR)
Barisione, Chiara (AUTHOR)
Ferrari, Pier Francesco (AUTHOR)
Palombo, Domenico (AUTHOR)
Pratesi, Giovanni (AUTHOR)
Pokaż więcej
Źródło:
Journal of Clinical Medicine. Jul2022, Vol. 11 Issue 13, p3638-N.PAG. 20p.
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies